Literature DB >> 10967371

Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.

A Coppen1, J Bailey.   

Abstract

BACKGROUND: A consistent finding in major depression has been a low plasma and red cell folate which has also been linked to poor response to antidepressants. The present investigation was designed to investigate whether the co-administration of folic acid would enhance the antidepressant action of fluoxetine.
METHODS: 127 patients were randomly assigned to receive either 500 microg folic acid or an identical looking placebo in addition to 20 mg fluoxetine daily. All patients met the DSM-III-R criteria for major depression and had a baseline Hamilton Rating Scale (17 item version) score for depression of 20 or more. Baseline and 10-week estimations of plasma folate and homocysteine were carried out.
RESULTS: Patients receiving folate showed a significant increase in plasma folate. This was less in men than in women. Plasma homocysteine was significantly decreased in women by 20.6%, but there was no significant change in men. Overall there was a significantly greater improvement in the fluoxetine plus folic acid group. This was confined to women where the mean Hamilton Rating Scale score on completion was 6.8 (S.D. 4. 1) in the fluoxetine plus folate group, as compared to 11.7 (S.D. 6. 7) in the fluoxetine plus placebo group (P<0.001).A percentage of 93. 9 of women, who received the folic acid supplement, showed a good response (>50% reduction in score) as compared to 61.1% of women who received placebo supplement (P<0.005). Eight (12.9%) patients in the fluoxetine plus folic acid group reported symptoms possibly or probably related to medication, whereas in the fluoxetine plus placebo group 19 (29.7%) patients reported such symptoms (P<0.05). LIMITATIONS AND
CONCLUSIONS: Folic acid is a simple method of greatly improving the antidepressant action of fluoxetine and probably other antidepressants. Folic acid should be given in doses sufficient to decrease plasma homocysteine. Men require a higher dose of folic acid to achieve this than women, but more work is required to ascertain the optimum dose of folic acid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967371     DOI: 10.1016/s0165-0327(00)00153-1

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  60 in total

Review 1.  Benefits and risks of folic acid to the nervous system.

Authors:  E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

Review 2.  Folic acid, ageing, depression, and dementia.

Authors:  E H Reynolds
Journal:  BMJ       Date:  2002-06-22

Review 3.  Is there a personalized medicine for mood disorders?

Authors:  Lucie Bartova; Andreas Berger; Lukas Pezawas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-19       Impact factor: 5.270

Review 4.  [Ethical implications of placebo-controlled clinical trials for psychotropic drugs].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

Review 5.  Neuroprotection by spice-derived nutraceuticals: you are what you eat!

Authors:  Ramaswamy Kannappan; Subash Chandra Gupta; Ji Hye Kim; Simone Reuter; Bharat Bhushan Aggarwal
Journal:  Mol Neurobiol       Date:  2011-03-01       Impact factor: 5.590

6.  Women with depression should be offered folic acid.

Authors:  Jonathan Melong; David Gardner
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

7.  The efficacy of vitamins for reducing or preventing depression symptoms in healthy individuals: natural remedy or placebo?

Authors:  Alison America; Leonard S Milling
Journal:  J Behav Med       Date:  2008-04

Review 8.  Complementary and alternative medicine therapies for perinatal depression.

Authors:  Kristina M Deligiannidis; Marlene P Freeman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2013-08-26       Impact factor: 5.237

Review 9.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

10.  Augmentation treatment in major depressive disorder: focus on aripiprazole.

Authors:  J Craig Nelson; Andrei Pikalov; Robert M Berman
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.